|
新聞出版品
Gastrointestinal Drug News
Gastrointestinal Drug News
|
Gastrointestinal Drug News 是由出版商Espicom Business Intelligence在出版的。
這份英文新聞出版品價格從美金690起跳。
本新聞資料內容包括Espicom公司的研究人員及編輯透過企業・研究機構、會議等蒐集的胃腸藥相關最新新聞，透過網路即時提供。
提供内容
- 所有種類的胃腸藥及其開發動向等相關最新新聞全文
- 方便取得最新資訊的界面
- 包括2,120則以上報導的廣泛內容資料庫
- 迅速且高效率的搜尋功能
- 每日&每週電子郵件通知
- RSS訂閱功能
Abstract
These days we all suffer from information overload. To overcome this problem,
the Gastrointestinal Drug News service focuses specifically on GI
drugs, delivering the information you need in a timely, flexible and
convenient format.
Long gone are the days when the GI market was dominated by H2 antagonists and
PPIs with the focus very much on conditions of the upper GI tract. The
treatment of GORD continues to be a growth market, but now growing clinical
awareness and improving rates of diagnosis are seeing conditions such as IBD
(ulcerative colitis, Crohn' s disease) and IBS take centre stage in future
plans - indeed, many feel that the potential patient population for these
conditions is only now beginning to be recognised.
For pharmaceutical company executives, researchers and commercial managers,
this sector is taking an important role in the industry' s plans; staying in
touch with the latest twists and turns, however, is another matter. That is
why this new, daily-updated online information service is essential.
The Gastrointesinal Drugs News information service provides:
- The full text of the latest news reported on all types of GI drugs and
their development
- An easy-to-use interface that immediately takes you to the most recently
updated information
- An extensive archive of over 2,120 articles which makes the service a
valuable tracking and research tool
- A fast and effective search facility allowing you to identify information
relevant to you
- Daily or weekly email alerts which will ensure you know when new
information is added
- An RSS feed facility
Every day, Espicom' s researchers and editors
- Track the companies and research organisations that are shaping the
industry
- Report the latest developments in current and up coming GI drugs
- Monitor results from major conferences and meetings
|
